Pulsatile GH Therapy Mimicking Exercise-Induced IGF-1 Elevation to Avoid Metabolic Toxicity in Aging

Yuki Dlamini (DPhil)· Mar 23, 2026

Mechanism: Pulsatile GH therapy, mimicking exercise, maintains hepatic STAT5 signaling by allowing SOCS proteins to degrade between pulses, thereby preserving insulin receptor sensitivity. Readout: Readout: This approach elevates IGF-1 levels by ~30% while maintaining metabolic safety and baseline SOCS2 mRNA, unlike continuous GH which induces insulin resistance.

Hypothesis

We propose that administering recombinant human growth hormone in short, nocturnal pulses aligned with endogenous slow‑wave sleep GHRH surges will raise serum IGF-1 to levels comparable with exercise training in older adults, yet will not provoke insulin resistance or other metabolic adverse effects.

Mechanistic Rationale

GH pulsatility preserves hepatic STAT5 signaling while limiting SOCS induction – Continuous GH exposure drives sustained JAK2-STAT5 activation that upregulates suppressors of cytokine signaling (SOCS2/3), which blunt insulin receptor substrate phosphorylation and promote hepatic insulin resistance. In contrast, intermittent GH spikes allow SOCS proteins to degrade between pulses, maintaining insulin signaling fidelity. This principle is supported by rodent models where pulsatile GH restores insulin sensitivity despite elevated IGF-1[[https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.667355/full]].
Exercise‑like IGF-1 production via hepatic IGF‑1 gene transcription – Nocturnal GH pulses amplify the natural sleep‑associated IGF‑1 surge, stimulating hepatic IGF‑1 synthesis without the chronic elevation seen with daily injections. Exercise raises IGF‑1 through a similar pulsatile pattern, which explains its metabolic safety[[https://pmc.ncbi.nlm.nih.gov/articles/PMC5938552/]].
Decoupling from inflammaging‑driven insulin resistance – By avoiding constant GH receptor activation, the hypothesis reduces GH‑induced SOCS-mediated interference with insulin signaling, allowing the anti‑inflammatory benefits of senolytic strategies (e.g., dasatinib+quercetin) to predominate[[https://pmc.ncbi.nlm.nih.gov/articles/PMC12408309/]].

Testable Predictions

IGF-1 elevation – Six months of nocturnal pulsatile GH (0.1 mg/kg, 3×/week) will increase serum IGF-1 by ~30 % (similar to resistance‑plus‑aerobic exercise[[https://pmc.ncbi.nlm.nih.gov/articles/PMC12408309/]]).
Metabolic safety – Fasting insulin, HOMA‑IR, and oral glucose tolerance will not differ from placebo, whereas continuous daily GH will raise HOMA‑IR by >20 %[[https://pubmed.ncbi.nlm.nih.gov/16042366/]].
Body composition vs. function – Lean mass will increase, but muscle strength and gait speed will improve only when pulsatile GH is combined with low‑intensity resistance training, mirroring the functional gains seen with exercise alone[[https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1549453/full]].
Molecular markers – Liver SOCS2 mRNA will remain baseline in the pulsatile group but rise significantly in the continuous GH group, correlating with insulin resistance scores.

Potential Confounders and Controls

Sleep architecture – Participants with untreated sleep apnea will be excluded or treated with CPAP to ensure intact slow‑wave sleep.
Baseline inflammation – High-sensitivity CRP will be measured; stratified randomization will balance inflammagenic burden.
Adherence monitoring – Micro‑dialysis pumps with event logs will verify pulse timing.

If pulsatile GH reproduces exercise‑like IGF-1 benefits without metabolic harm, it would reframe somatopause as a maladaptive loss of endogenous pulsatility rather than an adaptive protective decline, opening a safer pharmacological avenue for age‑related frailty.